Cisplatin: Mode of Cytotoxic Action and Molecular Basis of Resistance
Overview
Oncology
Authors
Affiliations
Cisplatin is one of the most potent antitumor agents known, displaying clinical activity against a wide variety of solid tumors. Its cytotoxic mode of action is mediated by its interaction with DNA to form DNA adducts, primarily intrastrand crosslink adducts, which activate several signal transduction pathways, including those involving ATR, p53, p73, and MAPK, and culminate in the activation of apoptosis. DNA damage-mediated apoptotic signals, however, can be attenuated, and the resistance that ensues is a major limitation of cisplatin-based chemotherapy. The mechanisms responsible for cisplatin resistance are several, and contribute to the multifactorial nature of the problem. Resistance mechanisms that limit the extent of DNA damage include reduced drug uptake, increased drug inactivation, and increased DNA adduct repair. Origins of these pharmacologic-based mechanisms, however, are at the molecular level. Mechanisms that inhibit propagation of the DNA damage signal to the apoptotic machinery include loss of damage recognition, overexpression of HER-2/neu, activation of the PI3-K/Akt (also known as PI3-K/PKB) pathway, loss of p53 function, overexpression of antiapoptotic bcl-2, and interference in caspase activation. The molecular signature defining the resistant phenotype varies between tumors, and the number of resistance mechanisms activated in response to selection pressures dictates the overall extent of cisplatin resistance.
Wei Q, Xiao Y, Wu Q, Jing C, Dong Z, Chen P Int J Mol Sci. 2025; 26(5).
PMID: 40076516 PMC: 11900216. DOI: 10.3390/ijms26051890.
MTMR6 downregulation contributes to cisplatin resistance in oral squamous cell carcinoma.
Lee K, Oh S, Lee H, Kwon T, Kim J, Shin C Cancer Cell Int. 2025; 25(1):30.
PMID: 39891222 PMC: 11783708. DOI: 10.1186/s12935-025-03654-9.
Impacts of amino acid-linked platinum(II) complexes on DNA structure.
Shrestha D, Kimutai B, Chow C J Biol Inorg Chem. 2025; .
PMID: 39853368 DOI: 10.1007/s00775-025-02097-x.
Lyu S, Meshesha S, Hong C Int J Mol Sci. 2025; 26(1.
PMID: 39796221 PMC: 11719730. DOI: 10.3390/ijms26010366.
Olajossy B, Wronski N, Madej E, Komperda J, Szczygiel M, Wolnicka-Glubisz A Biomolecules. 2025; 14(12.
PMID: 39766280 PMC: 11674099. DOI: 10.3390/biom14121573.